Targeting nevirapine delivery across human brain microvascular endothelial cells using transferrin-grafted poly(lactide-co-glycolide) nanoparticles

Nanomedicine

Volumn 6, Issue 6, 2011, Pages 1011-1026

  Kuo, Yung Chih ^a   Lin, Pei I ^a   Wang, Cheng Chin ^a  

^a NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

Author keywords

brain microvascular endothelial cell; nanoparticle; nevirapine; permeability; poly(lactide co glycolide); transferrin

Indexed keywords

DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; NANOPARTICLE; NEVIRAPINE; POLYGLACTIN; TRANSFERRIN; TRANSFERRIN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BRAIN CELL; CELL VIABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG TRANSPORT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MICROVASCULAR ENDOTHELIAL CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SECRETION;

BRAIN; CELL LINE; DRUG CARRIERS; ENDOTHELIAL CELLS; HUMANS; LACTIC ACID; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; NEVIRAPINE; POLYGLYCOLIC ACID; TRANSFERRIN;

EID: 80052087097     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.25     Document Type: Article

References (99)

1. Pang S, Koyangi Y, Miles S, Wiley C, Harry V, Chen I. High levels of unintegrated HIV-1 DNA in brain tissue of AIDS dementia patients. Nature 34, 85-89 (1990).
2. Gloor SM, Wachtel M, Bolliger MF, Ishihara H, Landmann R, Frei K. Molecular and cellular permeability control at the blood-brain barrier. Brain Res. Rev. 36, 258-264 (2001).
3. Béduneaua A, Saulnier P, Benoit JP. Active targeting of brain tumors using nanocarriers. Biomaterials 28, 4947-4967 (2007).
4. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles for controlled drug delivery: A review of the state of the art. Eur. J. Pharm. Biopharm. 50, 161-177 (2000).
5. Zhang Y, Zhu S, Yin L, Qian F, Tang C, Yin C. Preparation, characterization and biocompatibility of poly(ethylene glycol)-poly(N-butyl cyanoacrylate) nanocapsules with oil core via miniemulsion polymerization. Eur. Polym. J. 44, 1654-1661 (2008).
6. Kuo YC. Loading efficiency of stavudine on polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate copolymer nanoparticles. Int. J. Pharm. 290, 161-172 (2005).
7. Kuo YC, Chen HH. Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier. Int. J. Pharm. 327, 160-169 (2006).
8. Kuo YC, Su FL. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate- sulfopropylmethacrylate, and solid lipid nanoparticles. Int. J. Pharm. 340, 143-152 (2007).
9. Kuo YC, Kuo CY. Electromagnetic interference in the permeability of saquinavir across the blood-brain barrier using nanoparticulate carriers. Int. J. Pharm. 351, 271-281 (2008).
10. Kwon HY, Lee JY, Choi SW, Jang Y, Kim JH. Preparation of PLGA nanoparticles containing estrogen by emulsification-diffusion method. Colloid Surf. A 182, 123-130 (2001).
11. Xu Y, Du Y. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int. J. Pharm. 250, 215-226 (2003).
12. Verger ML, Fluiger L, Kim Y, Hoffman M, Maincent P. Preparation and characterization of nanoparticles containing an antihypertensive agent. Eur. J. Pharm. Biopharm. 46, 137-143 (1998).
13. Fontana G, Licciardi M, Mansueto S, Schillaci D, Giammona G. Amoxicillin-loaded polyethylcyano-acrylate nanoparticles: Influence of PEG coating on the particle size, drug release rate and phagocytic uptake. Biomaterials 22, 2857-2865 (2001).
14. Zambaux MF, Bonneaux F, Gref R et al. Influence of experimental parameters on the characteristics of poly (lactic acid) nanoparticles prepared by a double emulsion method. J. Control. Release 50, 31-40 (1998).
15. Bala I, Bhardwaj V, Hariharan S, Sitterberg J, Bakowsky U, Kumar Ravi MNV. Design of biodegradable nanoparticles: A novel approach to encapsulating poorly soluble phytochemical ellagic acid. Nanotechnology 16, 2819-2822 (2005).
16. Freiberg S, Zhu XX. Polymer microspheres for controlled drug release. Int. J. Pharm. 282, 1-18 (2004).
17. Dickinson E. Hydrocolloids as emulsifiers and emulsion stabilizers. Food Hydrocolloids 23, 1473-1482 (2009).
18. Nakase I, Gallis B, Takatani-Nakase T et al. Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of apoptosis. Cancer Lett. 274, 290-298 (2009). Dihydroartemisinin was tagged on transferrin for cancer therapy, where one transferrin carried 16 artemisinins.
19. Griffiths PD, Crossman AR. Autoradiography of transferrin receptors in the human brain. Neurosci. Lett. 211, 53-56 (1996).
20. Qian ZM, Li H, Sun H, Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 54, 561-587 (2002).
21. Wagner E, Curiel D, Cotton M. Delivery of drugs, proteins and genes into cells using transferring as a ligand for receptor-mediated endocytosis. Adv. Drug Delivery Rev. 14, 113-135 (1994).
22. Voinea M, Dragomir E, Manduteanu I, Simionescu M. Binding and uptake of transferring-bound liposomes targeted to transferrin receptors of endothelial cells. Vascul. Pharmacol. 39, 13-20 (2002).
23. Ke Y, Qian ZM. Brain iron metabolism: Neurobiology and neurochemistry. Prog. Neurobiol. 83, 149-173 (2007).
24. Ponka P, Lok CN. The transferrin receptor: Role in health and disease. Int. J. Biochem. Cell Biol. 31, 1111-1137 (1999).
25. Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin- and transferrinreceptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur. J. Pharm. Biopharm. 71, 251-256 (2009).
26. Soni V, Jain SK, Kohli DV. Potential of transferrin and transferrin conjugates of liposomes in drug delivery and targeting. Amer. J. Drug Deliv. 3, 155-170 (2005).
27. Huang RQ, Qu YH, Ke WL, Zhu JH, Pei YY, Jiang C. Efficient gene delivery targeted to the brain using a transferring-conjugated polyethylene glycol-modified polyamidoamine dendrimer. FASEB J. 21, 1117-1125 (2007).
28. Jefferies WA, Brandon MR, Hunt SV. Transferrin receptor on endothelium of brain capillaries. Nature 312, 162-163 (1984).
29. Jefferies WA, Brandon MR, Williams AF, Hunt SV. Analysis of lymphopoietic stem cells with a monoclonal antibody to the rat transferrin receptor. Immunology 54, 333-341 (1985).
30. Wu D, Pardridge WM. Pharmacokinetics and blood-brain barrier transport of an anti-transferrin receptor monoclonal antibody (OX26) in rats after chronic treatment with the antibody. Drug Metab. Dispos. 26, 937-939 (1998).
31. Anabousi S, Laue M, Lehr CM, Bakowsky U, Ehrhardt C. Assessing transferrin modification of liposomes by atomic force microscopy and transmission electron microscopy. Eur. J. Pharm. Biopharm. 60, 295-303 (2005).
32. Gu MQ, Yuan XB, Kang CS et al. biofunctionalization of PLA nanoparticles through amphiphilic polysaccharide coating and ligand coupling: Evaluation of biofunctionalization and drug releasing behavior. Carbohydr. Polym. 67, 417-426 (2007).
33. Li Y, Ogris M, Wagner E, Pelisek J, Rüffer M. Nanoparticles bearing polyethyleneglycol-coupled transferrin as gene carriers: Preparation and in vitro evaluation. Int. J. Pharm. 259, 93-101 (2003).
34. Sahoo SK, Labhasetwar V. Enhanced antiproliferative activity of transferring-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol. Pharm. 5, 373-383 (2005).
35. Antunes AMM, Duarte MP, Santos PP et al. Synthesis and characterization of DNA adducts from the HIV reverse transcriptase inhibitor nevirapine. Chem. Res. Toxicol. 21, 1443-1456 (2008).
36. Mugavero MJ, Hicks CB. HIV resistance and the effectiveness of combination antiretroviral treatment. Drug Discov. Today 1, 529-535 (2004).
37. Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin. Ther. 20, 1071-1092 (1998).
38. Kuo YC, Shih KH, Yang JT. Capillary electrophoresis of bone marrow stromal cells with the uptake of heparin-functionalized poly(lactide-co- glycolide) nanoparticles during differentiation towards neurons. Electrophoresis 31, 315-323 (2010).
39. Haesslein A, Hacker MC, Mikos AG. Effect of macromer molecular weight on in vitro ophthalmic drug release from photo-crosslinked matrices. Acta Biomater. 4, 1-10 (2008).
40. Faisant N, Akiki J, Siepmann F, Benoit JP, Siepmann J. Effects of the type of release medium on drug release from PLGA-based microparticles: Experiment and theory. Int. J. Pharm. 314, 189-197 (2006).
41. Klose D, Siepmann F, Elkharraz K, Krenzlin S, Siepmann J. How porosity and size affect the drug release mechanisms from PLGA-based microparticles. Int. J. Pharm. 314, 198-206 (2006).
42. Nafee N, Schneider M, Schaefer UF, Lehr CM. Relevance of the colloidal stability of chitosan/PLGA nanoparticles on their cytotoxicity profile. Int. J. Pharm. 381, 130-139 (2009).
43. De Stefano D, De Rosa G, Maiuri MC et al. Oligonucleotide decoy to NF-kB slowly released from PLGA microspheres reduces chronic inflammation in rat. Pharmacol Res. 60, 33-40 (2009).
44. Kuo YC, Chung CY. Transport of zidovudine- and lamivudine-loaded polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate nanoparticles across the in vitro blood-brain barrier: Characteristics of the drug-delivery system. J. Chin. Inst. Chem. Engrs. 36, 627-638 (2005).
45. Azuma R, Komuro M, Kawaguchi Y, Okudaira K, Hayashi M, Kiwada H. Comparative analysis of in vitro and in vivo pharmacokinetics parameters related to individual variability of GST-21 in canine. Drug Metab. Pharmacokinet. 17, 75-82 (2002).
46. Iwatmbo T, Hirota N, Ooie T et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther. 73, 147-171 (1997).
47. Gunaratna C. Pharmacokinetics in drug discovery: A primer for bioanalytical chemists, part II. Curr. Sep. 19, 87-92 (2010).
48. Ramachandran G, Hemanthkumar AK, Rajasekaran S et al. Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration. J. Acquir. Immune. Defic. Syndr. 42, 36-41 (2006).
49. Torimoto N, Ishii I, Hata M et al. Direct interaction between substrates and endogenous steroids in the active site may change the activity of cytochrome P450 3A4. Biochemistry 42, 15068-15077 (2003).
50. Agarwal V, Kommaddi RP, Valli K et al. Drug metabolism in human brain: High levels of cytochrome P4503A43 in brain and metabolism of anti-anxiety drug alprazolam to its active metabolite. PLoS ONE 3, E2337 (2008).
51. Pai HV, Upadhya SC, Chinta SJ, Hegde SN, Ravindranath V. Differential metabolism of alprazolam by liver and brain cytochrome (P4503A) to pharmacologically active metabolite. Pharmacogenomics J. 2, 243-258 (2002).
52. Van Rijen HVM, Van Kempen MJA, Analbers LJS et al. Gap junctions in human umbilical cord endothelial cells contain multiple connexins. Am. J. Physiol. Cell Physiol. 272, C117-C130 (1997).
53. Kuo YC. Effect of non-instantaneous disposition on the general measures of distribution kinetics in a modified mammillary compartmental model. J. Chin. Inst. Eng. 27, 231-242 (2004).
54. Sun J, Deng C, Chen X et al. Self-assembly of polypeptide-containing ABC-type triblock copolymers in aqueous solution and its pH dependence. Biomacromolecules 8, 1013-1017 (2007).
55. Hideki M, Yoshiaki K, Toshiyuki N, Tomoaki H, Hirofumi T, Masao K. Influence of the degrees of hydrolyzation and polymerization poly(vinylalcohol) on the preparation and properties of poly(dl-lactide-co-glycolide) nanoparticle. Int. J. Pharm. 149, 43-49 (1997).
56. Kuo YC, Shih KH. Loading efficiency and surface conductance of heparin-modified poly(lactide-co-glycolide) nanoparticles. Colloids Surf. B 71, 282-287 (2009).
57. Kuo YC, Chen IC. Evaluation of surface charge density and surface potential by electrophoretic mobility for solid lipid nanoparticles and human brain-microvascular endothelial cells. J. Phys. Chem. B. 111, 11228-11236 (2007).
58. Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. PLGA nanoparticles prepared by nanoprecipitation: Drug loading and release studies of a water soluble drug. J. Control. Release 57, 171-185 (1999).
59. Italia JL, Bhatt DK, Bhardwaj V, Tikoo K, Kumar MN. PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. J. Control. Release 119, 197-206 (2007).
60. Kuo YC, Chen HH. Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles. Int. J. Pharm. 365, 206-213 (2009).
61. Tros de Ilarduya C, Düzgünes N. Efficient gene transfer by transferrin lipoplexes in the presence of serum. Biochim. Biophys. Acta 1463, 333-342 (2000).
62. Kuo YC, Lin SC. Effect of glutamate on the electrical properties of cationic solid lipid nanoparticles containing stearylamine and dioctadecyldimethyl ammonium bromide. J. Phys. Chem. B. 112, 4454-4460 (2008).
63. Kuo YC, Wang CC. Electrophoresis of human brain microvascular endothelial cells with uptake of cationic solid lipid nanoparticles: Effect of surfactant composition. Colloids Surf. B 76, 286-291 (2010).
64. Chang J, Jallouli Y, Kroubi M et al. Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier. Int. J. Pharm. 379, 285-292 (2009).
65. Zolnik BS, Burgess DJ. Effect of acidic pH on PLGA microsphere degradation and release. J. Control. Release 122, 338-344 (2007).
66. Faisant N, Siepmann J, Benoit JP. PLGA-based microparticles: Elucidation of mechanisms and a new, simple mathematical model quantifying drug release. Eur. J. Pharm. Sci. 15, 355-366 (2002).
67. Yoo JY, Kim JM, Seo KS, Jeong YK, Lee HB, Khang G. Characterization of degradation behavior for PLGA in various pH condition by simple liquid chromatography method. Biomed. Mater. Eng. 15, 279-288 (2005).
68. Loo JS, Ooi CP, Boey FY. Influence of electron-beam radiation on the hydrolytic degradation behaviour of poly(lactide-co-glycolide) (PLGA). Biomaterials 26, 3809-3817 (2005).
69. Tang Y, Singh J. Controlled delivery of aspirin: Effect of aspirin on polymer degradation and in vitro release from PLGA based phase sensitive systems. Int. J. Pharm. 357, 119-125 (2008).
70. Zolnik BS, Leary PE, Burgess DJ. Elevated temperature accelerated release testing of PLGA microspheres. J. Control. Release 112, 293-300 (2006).
71. Li X, Ding L, Xu Y, Wang Y, Ping Q. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Int. J. Pharm. 373, 116-123 (2009).
72. Goodman CM, McCusker CD, Yilmaz T, Rotello VM. Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. Bioconjug. Chem. 15, 897-900 (2004).
73. Muller RH, Maassen S, Weyhers H, Specht F, Lucks JS. Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. Int. J. Pharm. 138, 85-94 (1996).
74. Catelas I, Petit A, Marchand R, Zukor DJ, Yahia L'H, Huk OL. Cytotoxicity and macrophage cytokine release induced by ceramic and polyethylene particles in vitro. J. Bone Joint Surg. 81-B, 516-521 (1999).
75. Kim SB, Ozawa T, Tao H, Umezawa Y. A proinflammatory cytokine sensor cell for assaying inflammatory activities of nanoparticles. Anal. Biochem. 362, 148-150 (2007).
76. Jones CF, Grainger DW. In vitro assessments of nanomaterial toxicity. Adv. Drug Delivery Rev. 61, 438-456 (2009).
77. Kimura H, Gules I, Meguro T, Zhang JH. Cytotoxicity of cytokines in cerebral microvascular endothelial cell. Brain Res. 990, 148-156 (2003).
78. Callahan MK, Williams KA, Kivisäkk P, Pearce D, Stins MF, Ransohoff RM. CXCR3 marks CD4+ memory T lymphocytes that are competent to migrate across a human brain microvascular endothelial cell layer. J. Neuroimmunol. 153, 150-157 (2004).
79. Kuo YC, Chen HH. Effect of electromagnetic field on endocytosis of cationic solid lipid nanoparticles by human brain-microvascular endothelial cells. J. Drug Target. 18, 447-456 (2010).
80. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Delivery Rev. 47, 65-81 (2001).
81. Glynn SL, Yazdanian M. In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. J. Pharm. Sci. 87, 306-310 (1998).
82. Voinea M, Dragomir E, Manduteanu I, Simionescu M. Binding and uptake of transferrin-bound liposomes targeted to transferring receptors of endothelial cells. Vascul. Pharmacol. 39, 13-20 (2002).
83. Li H, Sun H, Qian ZM. The role of the transferring-transferrin-receptor system in drug delivery and targeting. Trends Pharmacol. Sci. 23, 206-209 (2002).
84. Visser CC, Stevanovic S, Voorwinden LH et al. Targeting liposomes with protein drugs to the blood-brain barrier in vitro. Eur. J. Pharm. Sci. 25, 299-305 (2005).
85. Kuo YC, Lin CW. Impact of arginine-modified solid lipid nanoparticles on the membrane charge of human brain-microvascular endothelial cells. Colloids Surf. B 72, 201-207 (2009).
86. Kuo YC, Lin TW. Electrophoretic mobility, zeta potential, and fixed charge density of bovine knee chondrocytes, methylmethacrylate- sulfopropylmethacrylate, polybutylcyanoacrylate, and solid lipid nanoparticles. J. Phys. Chem. B. 110, 2202-2208 (2006).
87. Kuo YC, Lin CW. Effect of electromagnetic field and surface modification on the electrical behavior of novel solid lipid nanoparticles covered with l-arginine. Colloids Surf. B 71, 45-51 (2009).
88. Labhasetwar V, Song C, Humphrey W, Shebuski R, Levy RJ. Arterial uptake of biodegradable nanoparticles: Effect of surface modifications. J. Pharm. Sci. 87, 1229-1234 (1998).
89. Lu W, Wan J, She Z, Jiang X. Brain delivery property and accelerated blood clearance of cationic albumin conjugated PEGylated nanoparticles. J. Control. Release 118, 38-53 (2007). n Cationic bovine serum albumin was conjugated with PEGylated polylactic acid for absorptive-medicated transcytosis across the blood-brain barrier.
90. Lu W, Zhang Y, Tan YZ, Hu KL, Jiang XG, Fu SK. Cationic albumin-conjugated PEGylated nanoparticles as novel drug carrier for brain delivery. J. Control. Release 107, 428-448 (2005).
91. Sun W, Xie C, Wang H, Hu Y. Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials 25, 3065-3071 (2004).
92. Kreuter J. Application of nanoparticles for the delivery of drugs to the brain. Int. Congr. Ser. 1277, 85-94 (2005).
93. Sun H, Li H, Sadler PJ. Transferrin as a metal ion mediator. Chem. Rev. 99, 2817-2842 (1999).
94. Zak O, Ikuta K, Aisen P. The synergistic anion-binding sites of human transferrin: Chemical and physiological effects of site-directed mutagenesis. Biochemistry 41, 7416-7423 (2002).
95. Zak O, Trinder D, Aisen P. Primary receptor-recognition site of human transferrin is in the C-terminal lobe. J. Biol. Chem. 269, 7100-7114 (1994).
96. Mason AB, Tam BM, Woodworth RC et al. Receptor recognition sites reside in both lobes of human serum transferrin. Biochem. J. 326, 77-85 (1997).
97. Veldkamp AI, Weverling GJ, Lange JM et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 15, 1089-1095 (2001).
98. Murphy R, Montaner J. Nevirapine: A review of its development, pharmacological profile and potential clinical use. Exp. Opin. Invest. Drugs 5, 1183-1199 (1996).
99. Mehnert W, Mader K. Solid lipid nanoparticles. Production, characterization and applications. Adv. Drug Deliv. Rev. 47, 165-196 (2001).